Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs. Our company management and advisors consist of veteran pharmaceutical executives with multiple prior successes in the development and commercialization of many blockbuster biologics currently in the market. Tavotek has 3 diverse R&D platform for biologics: TavoSelect™ (Phage Display Library), TavoPrecise™ (Tissue-specific biologics engineering platform), and TavoELITE™ (Intracellular Undruggable Target platform). Along with these platforms, Tavotek has a rich and diverse pipeline of product candidates focused on cancers, autoimmune conditions, and infectious diseases in various stages of development. We are globally connected with operations in Asia and North America. Our development strategy includes organic growth, biopharma collaboration, and potential clinical stage asset licensing.